The role of miRNAs inhibitors in the treatment of metabolic dysfunction-associated steatotic liver disease

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) occupies a leading place in modern hepatology. A growing body of literature identifies MASLD as a global epidemic. Accumulated data from hepatology studies support the view that MASLD represents a hepatic manifestation of a systemic metabolic disease. In recent years, there has been increasing interest among researchers in elucidating the role of epigenetic modifications in the treatment of MASLD. In contrast to traditional therapies, drugs targeting epigenetic-modifying enzymes, such as micro ribonucleic acid (miRNA) inhibitors, have been developed with a focus on gene regulation.